+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

  • ID: 4754205
  • Clinical Trials
  • February 2019
  • Region: Global
  • 156 pages
  • VPA Research
1 of 2
The ongoing clinical trial research report- “2019 Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials Study” analyzes the current scenario of all active Non Alcoholic Fatty Liver Disease (NAFLD) trials across the world. The report presents top level analysis of global Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Non Alcoholic Fatty Liver Disease (NAFLD) trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials by
  • Region (Asia Pacific, Europe, Middle East Africa and Americas)
  • Countries
  • Trial Phase
  • Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
  • Type of the trial (Interventional, Observational)
  • Sponsor Type (Companies, Universities, Government Bodies etc)
  • Enrollment across types, sponsor types, geographies, current status and phases
The report also identifies the potential drug candidates under development for treatment of Non Alcoholic Fatty Liver Disease (NAFLD) on the basis of intervention type ongoing Non Alcoholic Fatty Liver Disease (NAFLD) trials.

The research work is prepared through extensive and continuous research on Non Alcoholic Fatty Liver Disease (NAFLD) trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Non Alcoholic Fatty Liver Disease (NAFLD) patients are identified
  • The report includes panorama of ongoing Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 2
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
2.2.1 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Region
2.2.2 Average Enrollment of Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
2.2.3 Companies participating in Ongoing Trials
2.2.4 Drugs under Study for Non Alcoholic Fatty Liver Disease (NAFLD) Treatment, 2019

3. Region wise Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
3.1 Asia Pacific Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Country
3.2 Europe Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Country
3.3 North America Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Country
3.4 Middle East and Africa Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Country
3.5 South and Central America Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials by Country

4. Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Trends
4.1 Start Year wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
4.2 Phase wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
4.3 Trial Status wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
4.4 Trial Type wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials

5. Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment Trends
5.1 Average Enrollment in Non Alcoholic Fatty Liver Disease (NAFLD) Trials by Year
5.2 Average Enrollment in Non Alcoholic Fatty Liver Disease (NAFLD) Trials by Phase
5.3 Average Enrollment in Non Alcoholic Fatty Liver Disease (NAFLD) Trials by Status
5.4 Average Enrollment in Non Alcoholic Fatty Liver Disease (NAFLD) Trials by Type of Trial

6. Companies Participating in Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
6.1 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Trials by Sponsor Type
6.2 Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots - Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Trials - Phase 1
7.2 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Trials - Phase 2
7.3 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Trials - Phase 3
7.4 Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Trials - Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Figure 7: North America - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Figure 9: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Phase
Figure 10: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Trial Status
Figure 11: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Type
Figure 12: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Sponsor Type
Figure 13: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials by Leading Sponsors
Figure 14: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Phase
Figure 15: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Trial Status
Figure 16: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Type
Figure 17: Non Alcoholic Fatty Liver Disease (NAFLD) - Average Enrolment by Type of Sponsors
Figure 18: Non Alcoholic Fatty Liver Disease (NAFLD) - Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Non Alcoholic Fatty Liver Disease (NAFLD) Ongoing Clinical Trials Snapshot - 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Table 5: Europe - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Table 7: North America - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Ongoing Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Phase
Table 15: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Trial Status
Table 16: Non Alcoholic Fatty Liver Disease (NAFLD) Average Enrollment by Type
Table 17: Non Alcoholic Fatty Liver Disease (NAFLD) - Average Enrolment by Type of Sponsors
Table 18: Non Alcoholic Fatty Liver Disease (NAFLD) - Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll